Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0432222 (SEM)
 47,337 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

In order to investigate plasma prolactin and thyroid-stimulating-hormone (TSH) concentration and pituitary reserve of these two hormones in patients with breast cancer, following examinations were carried out. Plasma prolactin concentration was measured before and 15, 30, 60, 90 minutes after the 500mug of thyrotropin-releasing-hormone (TRH) i.v. injection in 22 patients with breast cancer and 4 patients with benign breast disease. All patients did not take any hormonal therapy and any medication inducing prolactin secretion. Ten healthy females were also tested as controls. Plasma prolactin concentration was estimated by a double antibody radioimmunoassay (RIA) technique using hPRL RIA kit provided by NIAMDD. The basal prolactin concentration in patients with breast cancer was 18.6 +/- ng/ml (Mean +/- SEM), and it was slightly higher than the control group (14.7 +/- 2.2 ng/ml), but not statistically significant. In 6 out of 22 patients with breast cancer, high plasma prolactin concentrations more than 25 ng/ml were observed. The maximal plasma prolactin concentration following the TRH injection was obtained at 15-30 minutes after TRH in most patients with breast cancer. The maximal value was 87.4 +/- 9.2 ng/ml, and it was near the upper limit of normal range of prolactin response, and not significantly higher than the maximal value in the control group (59.7 +/- 5.7 ng/ml). In 7 patients with breast cancer, the maximal prolactin values more than 100 ng/ml were obtained after TRH injection. There was no statistically significant difference between early breast cancer group (TNM: stage I & II, N=14) and advanced breast cancer group (TNM: stage III & IV, N=6) in both the plasma prolactin concentration and the pituitary prolactin reserve...
 ...
PMID:[Plasma prolactin and thyroid-stimulating-hormone (TSH) in patients with breast cancer (author's transl)]. 82 85

Although several biomarkers have been tested, Dukes' (or TNM) stage at diagnosis is still considered the only prognostic factor of clinical relevance in colorectal cancer. Among the various biomarkers, the fraction of cells engaged in DNA synthesis has been extensively investigated as an indicator of tumor aggressiveness. Bromodeoxyuridine (BUdR) is a non-radioactive thymidine analogue which is incorporated into DNA during the S-phase of cycling cells. In order to evaluate the relationships between cell kinetics and morphologic variables, 500 mg of BUdR were given i.v. to 46 patients with colorectal cancer prior to surgery. After operation, a large tumor sample was taken and processed for immunohistochemical detection of BUdR-labeled cells in various regions of the neoplasm and in normal colorectal mucosa. Smaller superficial tumor specimens were also incubated with 3H-thymidine (3H-TdR) for the autoradiographic identification of labeled cells. In the 43 evaluable tumors, the overall BUdR labeling index (BLI, percent of labeled cells) was significantly higher in carcinoma (20.30 +/- 0.86%, SEM) than in normal colonic mucosa (6.51 +/- 0.49%). BLIs in central and peripheral regions of carcinoma were closely correlated (r = 0.48, p = 0.003). In 21 neoplasms a high correlation between overall BUdR and 3H-TdR labeling index in the same tumor was observed (r = 0.57, p = 0.007). No evident association between overall BLI and clinical or morphologic parameters of the tumor was seen, including number of capillaries and ras-p21 protein expression. We conclude that BUdR immunostaining after in vivo administration of BUdR is a simple method for studying cell kinetics in various regions of colorectal cancer. BUdR labeling data are comparable to those obtained with in vitro incorporation of 3H-TdR.
 ...
PMID:Cell kinetics evaluation of colorectal tumors after in vivo administration of bromodeoxyuridine. 145 24

The authors have measured the androgen receptor concentrations in the cytosol and nucleus of 13 carcinoma of the prostate (CaP) patients and compared these values to those in an age-matched group of 23 patients with benign prostatic hyperplasia (BPH). Histologic classification of the tumors was carried out and the receptor content was correlated to the grade and stage of the disease. The mean +/- SEM receptor values for BPH (cytosol: 115 +/- 18 fmol/g tissue; nucleus: 140 +/- 34 fmol/g tissue) were not significantly different from those measured in CaP (cytosol: 105 +/- 23 fmol/g tissue; nucleus: 83 +/- 23 fmol/g tissue). There was a positive correlation between nuclear and cytosolic receptors in both BPH and CaP. Our data revealed, however, the absence of any correlation between histologic grade in CaP and receptor content. If, however, the tumors were classified according to the stage of the cancer using the TNM system, "early disease" tumors maintained significantly lower Gleason score (4.4 +/- 0.61) and receptor levels (cytosol: 63.8 +/- 31.2 fmol/g tissue; nucleus: 46.2 +/- 26.5 fmol/g tissue) than those measured in the "late disease" (Gleason score: 7.0 +/- 0.56; cytosol receptor: 146.2 +/- 20.5; nuclear receptor: 117.2 +/- 31.6) (P less than 0.05); therefore the staging of the disease bears a great impact on the capacity of the tumor to specifically bind androgens.
 ...
PMID:Androgen receptors in cancer of the prostate. Correlation with the stage and grade of the tumor. 242 68

We retrospectively analyzed experience with total gastrectomy (TG) for gastric carcinoma in 23 patients. The TNM stage was I in one patient, II in one patient, III in eight patients, and IV in 13. Linitis plastica was found in ten patients. The operation was considered curative in only eight patients (35%). There were 13 complications in eight patients. There were no operative deaths. The survival ranged from three to 36 months. The survival for curative TG was a mean of 21.2 months +/- 3.3 SEM; for palliative TG, mean survival was 10.1 months +/- 1.1 SEM (P less than .001). These results suggest that gastric carcinoma that extensively involves the fundus and/or the corpus continues to be highly lethal, even when these tumors can be resected with a TG. Furthermore, even when the operation is considered "curative" and can be done with little or no operative mortality, the average survival was at best 21 months.
 ...
PMID:Total gastrectomy for gastric carcinoma. 247 60

To determine whether patients from disadvantaged socioeconomic groups present with more advanced thyroid carcinoma or experience differing management and clinical outcomes, we retrospectively reviewed the charts of 292 patients seen at MD Anderson Cancer Center and Ben Taub General Hospital between 1987 and 1994. At diagnosis, the mean age was 42 +/- 16 years, 78% of patients were female, 76% of patients were low risk (TNM stage I or II), and 22% high risk (stage III or IV). Neighborhood income (+/- standard error of the mean [SEM]) (1990 census data) was lower in the high-risk group compared with the low-risk group (US dollars 26200 +/- 1670 vs. US dollars 30900 +/- 870, p = 0.012). Men were more likely than women to present at an older age (47.5 +/- 16.7 vs. 40.2 +/- 16.0, p = 0.0014) and in the high-risk group (46% vs. 15%, p < 0.0001). No socioeconomic factor (ethnicity, marital status, occupation prestige, neighborhood income, insurance type) influenced initial diagnostic assessment. Similarly, no socioeconomic factor influenced initial disease management or the type of follow-up received over the 12-year period. Married patients had a lower 5-year recurrence rate than those unmarried (18% vs. 32%, p = 0.03); however, this did not affect overall or disease-specific survival. Similarly, ethnicity, marital status, occupation prestige, and insurance type did not influence overall or disease-specific survival. Although 10-year overall survival rates were lower in patients in the lowest income quartile (57% vs. 70% for upper, p = 0.0024) and in men compared with women (39% vs. 76%, p < 0.0001), gender alone influenced 10-year disease-specific survival (80% for men, 89% for women, p = 0.047). In summary, no socioeconomic factor appears to affect initial treatment or follow-up pattern in patients with differentiated thyroid cancer. Income and gender may affect stage at initial disease presentation and may be risk factors affecting eventual clinical outcomes.
 ...
PMID:Socioeconomic factors and the presentation, management, and outcome of patients with differentiated thyroid carcinoma. 1249 79